Clearside Biomedical, Inc. announced that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD). Topline data results are expected in the third quarter of 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | -0.76% | -2.24% | +11.97% |
Apr. 16 | Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors | CI |
Mar. 18 | Clearside Biomedical Names Victor Chong Chief Medical Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.97% | 97.9M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD